Previous 10 | Next 10 |
home / stock / cybr / cybr articles
CyberArk Software Ltd. (NASDAQ:CYBR) inked a deal to acquire Venafi from Thoma Bravo for an enterprise value of $1.54 bill...
CyberArk Software Ltd (NASDAQ:CYBR) reported fiscal first-quarter 2024 revenue growth of 37% year-on-year to $221.55 million, beating the ...
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index future...
As the tech sector braces for its upcoming earnings season, Wedbush Securities analyst Daniel Ives provides a bullish outlook. Tech Sell-Off –...
CyberArk Software (NASDAQ:CYBR) has outperformed the market over the past 5 years by 2.97% on an annualized basis producing an average annual retur...
Market strategist Matt Orton has identified two under-the-radar U.S. small-cap companies that he believes have significant potential for growth. Wh...
Rize UCITS ICAV - Rize Cybersecurity Data Privacy ETF (NASDAQ:CYBR) has outperformed the market over the past 5 years by 5.88% on an annualized bas...
CyberArk Software (NASDAQ:CYBR) has outperformed the market over the past 5 years by 6.65% on an annualized basis producing an average annual retur...
CyberArk Software (NASDAQ:CYBR) has outperformed the market over the past 5 years by 13.39% on an annualized basis producing an average annual retu...
News, Short Squeeze, Breakout and More Instantly...
CyberArk Software Ltd. Company Name:
CYBR Stock Symbol:
NASDAQ Market:
CyberArk Software Ltd. Website:
A look at the top 10 most actives in the United States Conduit Pharmaceuticals Inc. (CDT) rose 40.0% to $0.3361 on volume of 63,970,490 shares Yoshitsu Co. Ltd (TKLF) rose 64.0% to $0.5024 on volume of 62,618,792 shares Silo Pharma Inc. (SILO) rose 91.8% to $2.0522 on volume of 59,055,593...
2024-07-11 07:30:04 ET Barclays analyst issues OVERWEIGHT recommendation for CYBR on July 11, 2024 05:35AM ET. The previous analyst recommendation was Overweight. CYBR was trading at $271.26 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...